Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%

Rapid COJEC vs standard induction therapies

Complete response · patients with high‐risk neuroblastoma

Rapid COJEC showed no clear difference in complete response compared with standard induction therapies (low certainty).

1 finding from 1 review

Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma 2015 · Cochrane Headline outcomes only
RR 0.99 [0.71, 1.38]
1 study · 170 participants
Low

Rapid COJEC vs standard induction therapies

Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate < 80 ml/... · patients with high‐risk neuroblastoma

1 finding from 1 review

Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 248 participants
Low

Rapid COJEC vs standard induction therapies

Treatment‐related mortality · patients with high‐risk neuroblastoma

Rapid COJEC showed no clear difference in treatment‐related mortality compared with standard induction therapies (low certainty).

1 finding from 1 review

Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma 2015 · Cochrane Headline outcomes only
RR 1.21 [0.33, 4.39]
1 study · 234 participants
Low

Rapid COJEC vs standard induction therapies

Overall survival · patients with high‐risk neuroblastoma

Rapid COJEC showed no clear difference in overall survival compared with standard induction therapies (low certainty).

1 finding from 1 review

Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma 2015 · Cochrane Headline outcomes only
HR 0.83 [0.63, 1.1]
1 study · 262 participants
Low

Rapid COJEC vs standard induction therapies

Progression‐free survival ‐ not reported · patients with high‐risk neuroblastoma

The review found no eligible studies for this question.

1 finding from 1 review

Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rapid COJEC vs standard induction therapies

Event‐free survival · patients with high‐risk neuroblastoma

Rapid COJEC showed no clear difference in event‐free survival compared with standard induction therapies (low certainty).

1 finding from 1 review

Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma 2015 · Cochrane Headline outcomes only
HR 0.86 [0.65, 1.13]
1 study · 262 participants
Low

Rapid COJEC vs standard induction therapies

Late non‐hematological toxicities: any complication, renal toxicity (Glomerular Filtration Rate < 80 ml/min per body surface area of 1.73 m2), ototoxicity (Brock grade 1 to 4), endocrine complications (see table of included studies for included di... · patients with high‐risk neuroblastoma

1 finding from 1 review

Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 57 participants
Low